ReviewF1000Research2016
Recent advances in understanding Type 1 Diabetes.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the association of Type I diabetes with sensorineural hearing loss.PloS one · 2024Pooled it
- Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines.BMC molecular and cell biology · 2023Article
- IL-6 in inflammation, autoimmunity and cancer.International immunology · 2021Review
- Protective Role of St. John's Wort and Its Components Hyperforin and Hypericin against Diabetes through Inhibition of Inflammatory Signaling: Evidence from In Vitro and In Vivo Studies.International journal of molecular sciences · 2020Review
- Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes.Frontiers in cell and developmental biology · 2020Article
- Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.Wellcome open research · 2020Article
- BET Proteins Are Required for Transcriptional Activation of the Senescent Islet Cell Secretome in Type 1 Diabetes.International journal of molecular sciences · 2019Article
- Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review.Journal of clinical & cellular immunology · 2019Article
- Human Leukocyte Antigen (HLA) and Islet Autoantibodies Are Tools to Characterize Type 1 Diabetes in Arab Countries: Emphasis on Kuwait.Disease markers · 2019Review
- An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes.JCI insight · 2017Article
- Type 1 Diabetes and Type 1 Interferonopathies: Localization of a Type 1 Common Thread of Virus Infection in the Pancreas.EBioMedicine · 2017Review
- Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?Journal of endocrinological investigation · 2017Review
- Type 1 Diabetes - A Clinical Perspective.Point of care · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes is a multifactorial disease in which genetic and environmental factors play a key role. The triggering event is still obscure, and so are many of the immune events that follow. In this brief review, we discuss the possible role of potential environmental factors and which triggers are believed to have a role in the disease. In addition, as the disease evolves, beta cells are lost and this occurs in a very heterogeneous fashion. Our knowledge of how beta cell mass declines and our view of the disease's pathogenesis are also debated. We highlight the major hallmarks of disease, among which are MHC-I (major histocompatibility complex class I) expression and insulitis. The dependence versus independence of antigen for the immune infiltrate is also discussed, as both the influence from bystander T cells and the formation of neo-epitopes through post-translational modifications are thought to influence the course of the disease. As human studies are proliferating, our understanding of the disease's pathogenesis will increase exponentially. This article aims to shed light on some of the burning questions in type 1 diabetes research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.